Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study
Brief Summary: This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative 3-arms of 140 patients (i.e. 420 total patients).

Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months


Options:
A: Arm Label: lack of drug prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HBPM 2500 UI anti Xa in one subcutaneous injection per day; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Arm Label: warfarine 1mg daily; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Intervention Type: DRUG; Name: warfarine - low molecular heparin; Assigned to Arm(s): HBPM 2500 UI anti Xa in one subcutaneous injection per day, warfarine 1mg daily
B: Arm Label: Treatment (chemotherapy, radiotherapy); Type: EXPERIMENTAL; Interventions: Drug: cyclophosphamide, Drug: cytarabine, Drug: daunorubicin hydrochloride, Drug: dexamethasone, Drug: doxorubicin hydrochloride, Drug: mercaptopurine, Drug: methotrexate, Drug: pegaspargase, Drug: thioguanine, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Treatment (chemotherapy, radiotherapy) | Intervention Type: DRUG; Name: cytarabine; Assigned to Arm(s): Treatment (chemotherapy, radiotherapy) | Intervention Type: DRUG; Name: daunorubicin hydrochloride; Assigned to Arm(s): Treatment (chemotherapy, radiotherapy) | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Treatment (chemotherapy, radiotherapy) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Treatment (chemotherapy, radiotherapy) | Intervention Type: DRUG; Name: mercaptopurine; Assigned to Arm(s): Treatment (chemotherapy, radiotherapy) | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Treatment (chemotherapy, radiotherapy) | Intervention Type: DRUG; Name: pegaspargase; Assigned to Arm(s): Treatment (chemotherapy, radiotherapy) | Intervention Type: DRUG; Name: thioguanine; Assigned to Arm(s): Treatment (chemotherapy, radiotherapy) | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Treatment (chemotherapy, radiotherapy) | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Treatment (chemotherapy, radiotherapy)
C: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution (placebo) | Arm Label: nadroparin calcium; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin calcium | Intervention Type: DRUG; Name: Nadroparin calcium; Assigned to Arm(s): nadroparin calcium | Intervention Type: DRUG; Name: saline solution (placebo); Assigned to Arm(s): saline solution

Answer: A